Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers
Negar Hosseinkhani, Mahdi Abdoli Shadbad, Mohammad Asghari Jafarabadi, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 19, pp. 10389-10389
Open Access | Times Cited: 20

Showing 20 citing articles:

Targeting the tumor microenvironment: Potential strategy for cancer therapeutics
Quratulain Babar, Ayesha Saeed, Tanveer A. Tabish, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2023) Vol. 1869, Iss. 6, pp. 166746-166746
Open Access | Times Cited: 44
Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours
Kamilla J. A. Bigos, Conrado Guerrero Quiles, Sapna Lunj, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 20
Current progress and challenges of immunotherapy in gastric cancer: A focus on CAR-T cells therapeutic approach
Mahshad Entezam, Mohammad‐Javad Sanaei, Yousef Mirzaei, et al.
Life Sciences (2023) Vol. 318, pp. 121459-121459
Closed Access | Times Cited: 22
Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy
Saud Almawash
Cancers (2025) Vol. 17, Iss. 5, pp. 880-880
Open Access
Dendritic cell-based cancer immunotherapy in the era of immune checkpoint inhibitors: From bench to bedside
Farid Ghorbaninezhad, Zahra Asadzadeh, Javad Masoumi, et al.
Life Sciences (2022) Vol. 297, pp. 120466-120466
Closed Access | Times Cited: 25
Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors
Martina Catalano, Sonia Shabani, Jacopo Venturini, et al.
Cancers (2022) Vol. 14, Iss. 24, pp. 6145-6145
Open Access | Times Cited: 18
A Systematic Review on PD-1 Blockade and PD-1 Gene-Editing of CAR-T Cells for Glioma Therapy: From Deciphering to Personalized Medicine
Mahdi Abdoli Shadbad, Nima Hemmat, Vahid Khaze, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 13
Dual silencing of tumor-intrinsic VISTA and CTLA-4 stimulates T-cell mediated immune responses and inhibits MCF7 breast cancer development
Negar Hosseinkhani, Nima Hemmat, Elham Baghbani, et al.
Gene (2023) Vol. 896, pp. 148043-148043
Closed Access | Times Cited: 7
Research advances in immune checkpoint drugs for non-small cell lung cancer
Yue Shen, Juan Chen, Xiangping Li
Journal of drug targeting (2023) Vol. 31, Iss. 7, pp. 700-713
Closed Access | Times Cited: 5
Targeting the Renin–angiotensin–aldosterone System (RAAS) for Cardiovascular Protection and Enhanced Oncological Outcomes: Review
J Pawlonka, Barbara Buchalska, Kasper Buczma, et al.
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 11, pp. 1406-1427
Open Access | Times Cited: 1
Molecular Profiling of Endometrial Cancer: An Exploratory Study in Aotearoa, New Zealand
Claire Henry, Khoi Phan, Elena J. Orsman, et al.
Cancers (2021) Vol. 13, Iss. 22, pp. 5641-5641
Open Access | Times Cited: 12
Comparative genomics reveals the presence of simple sequence repeats in genes related to virulence in plant pathogenic Pythium ultimum and Pythium vexans
Nahaa M. Alotaibi, Mοhd Saeed, Nawaf Alshammari, et al.
Archives of Microbiology (2023) Vol. 205, Iss. 7
Closed Access | Times Cited: 4
Double Guard Efficiency and Safety—Overcoming Resistance to Immunotherapy by Blocking or Stimulating Several Immune Checkpoints in Non-Small Cell Lung Cancer Patients
Ewa Kalinka‐Warzocha, Kamila Wojas‐Krawczyk, Paweł Krawczyk
Cancers (2023) Vol. 15, Iss. 13, pp. 3499-3499
Open Access | Times Cited: 4
The Combination of PD-L1 and CTLA-4 Suppression Significantly Decreased the Expression Levels of Cancer Stem Cell Factors in the Pancreatic Cancer Cell Line
Nazila Alizadeh, Tohid Kazemi, Nima Hemmat, et al.
ImmunoAnalysis (2023) Vol. 3, pp. 6-6
Open Access | Times Cited: 4
PD-1 and TIGIT coexpressing CD8 + CD103 + tissue-resident memory cells in endometrial cancer as potential targets for immunotherapy
Fang Jiang, Mingyi Mao, Shiyang Jiang, et al.
International Immunopharmacology (2023) Vol. 127, pp. 111381-111381
Closed Access | Times Cited: 4
Tumor-infiltrating CD8+ sub-populations in primary and recurrent glioblastoma: An in-silico study
Mahdi Abdoli Shadbad, Adib Miraki Feriz, Behzad Baradaran, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e27329-e27329
Open Access
Programmed death receptor-1/programmed death-ligand 1 inhibitors: Clinical progress and biomarker exploration in gastric cancer
Jin Shi, Xudong Song, Zihao Gao, et al.
Heliyon (2024) Vol. 10, Iss. 20, pp. e38710-e38710
Open Access
Investigation of the efficacy and safety of cryoablation and intra-arterial PD-1 inhibitor in patients with advanced disease not responding to checkpoint inhibitors: An exploratory study
Fuqun Wei, Rui Guo, Yan Yuan, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 3
Mechanisms of Resistance and Strategies to Combat Resistance in PD-(L)1 Blockade
John Moise, Jeevan Murthy, Dolma Dabir, et al.
Immuno (2022) Vol. 2, Iss. 4, pp. 671-691
Open Access | Times Cited: 2
Dual Silencing of Tumor-Intrinsic VISTA and CTLA-4 Stimulates T-Cell Mediated Immune Responses and Inhibits MCF7 Breast Cancer Development
Negar Hosseinkhani, Nima Hemmat, Elham Baghbani, et al.
(2023)
Closed Access
Page 1

Scroll to top